With 0.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.61 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.23 whereas the lowest price it dropped to was $2.05. The 52-week range on OSTX shows that it touched its highest point at $7.00 and its lowest point at $1.12 during that stretch. It currently has a 1-year price target of $13.00. Beta for the stock currently stands at -3.97.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of OSTX was down-trending over the past week, with a drop of -4.52%, but this was down by -9.44% over a month. Three-month performance surged to 16.57% while six-month performance rose 29.45%. The stock lost -50.70% in the past year, while it has lost -34.27% so far this year. A look at the trailing 12-month EPS for OSTX yields -0.74 with Next year EPS estimates of -0.30. For the next quarter, that number is -0.12. This implies an EPS growth rate of 31.14% for this year and 50.50% for next year. EPS is expected to grow by 82.16% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 79.38%.
Float and Shares Shorts:
At present, 29.66 million OSTX shares are outstanding with a float of 17.14 million shares on hand for trading. On 2025-09-15, short shares totaled 0.52 million, which was 163.0 higher than short shares on 1755216000. In addition to Mr. Paul A. Romness M.P.H. as the firm’s Founder, Chairman, President & CEO, Mr. Christopher P. Acevedo serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, OSTX reported revenue of $0.0 and operating income of -$4838728.0. The EBITDA in the recently reported quarter was -$4726150.0 and diluted EPS was -$0.19.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With OSTX analysts setting a high price target of 20.0 and a low target of 6.0, the average target price over the next 12 months is 12.058. Based on these targets, OSTX could surge 847.87% to reach the target high and rise by 184.36% to reach the target low. Reaching the average price target will result in a growth of 471.47% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.94739 being high and -$1.18595 being low. For OSTX, this leads to a yearly average estimate of -$1.06667. The surprise factor in the prior quarter was -$0.09. Based on analyst estimates, the high estimate for the next quarter is -$0.06 and the low estimate is -$0.18. The average estimate for the next quarter is thus -$0.12.
